This article is more than 5 years old. Information may no longer be current.

CDC publishes ACIP recommendations for HPV vaccination

CDC. MMWR. 2011;60(50):1705-1708.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The CDC recently published the Advisory Committee on Immunization Practices recommendations on the routine use of human papillomavirus vaccine.

In October, ACIP recommended routine use of quadrivalent HPV vaccine (HPV4; Gardasil, Merck) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 to 21 years who have not been vaccinated previously or who have not completed the three-dose series; males aged 22 to 26 years also may be vaccinated.

These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 to 26 years.

For special populations, including patients who are immunocompromised and for men who have sex with men, ACIP recommends routine vaccination with HPV4 for all males, including those who are immunocompromised, and vaccination through age 26 years for those who have not been vaccinated previously or who have not completed the three-dose series.

Additional information on ACIP recommendations is available at www.cdc.gov/vaccines/recs/acip/#recs.

Follow HemOncToday.com on Twitter.